Atlas Trials

Safety, Tolerability, and Pharmacokinetics Study of Elpipodect (MK-8189) in Participants With Schizophrenia and Healthy Participants (MK-8189-011)

Clinical trial NCT04506905 · COMPLETED

Trial details

NCT number
NCT04506905
Sponsor
Merck Sharp & Dohme LLC
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Schizophrenia
Start date
2020-08-28
Primary completion
2022-03-22
Enrollment
63

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.